CurrentUnitedHealthcarePolicy CS001NM.C

Ablative Treatment for Spinal Pain (for New Mexico Only)

This policy discusses clinical evidence, guideline recommendations, and positions regarding various spinal ablative procedures (thermal RFA, cooled RFA, pulsed RFA, cryodenervation, and intraosseous basivertebral nerve ablation/Intracept) for chronic low back pain and other spinal pain indications; it provides supporting information and references and updates to clinical evidence. It is informational for UnitedHealthcare coverage decision-making and must be applied alongside plan-specific contract requirements.

Policy Summary

PayerUnitedHealthcare

PolicyAblative Treatment for Spinal Pain (for New Mexico Only)

Policy CodePolicy N/A

Change Typeclarified

Effective DateMarch 1, 2026

Next Review DateN/A

Key ActionEvidence and trials specify BVNA candidates had Modic type 1 or 2 vertebral endplate changes between L3 and S1 documented on imaging; providers should document these findings when considering BVNA.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information.

mixedOverall evidence synthesis

3 yearsDuration of benefit reported

more trials neededEvidence gaps

Coverage summary

This policy provides an informational summary of clinical evidence, guideline recommendations, and positions regarding spinal ablative procedures — including thermal radiofrequency ablation (RFA) techniques and intraosseous basivertebral nerve ablation (BVNA/Intracept) — for chronic low back pain. It is intended to inform UnitedHealthcare decision-making but must be applied alongside applicable federal, state, and contractual plan requirements.

The coverage stance is mixed: guideline bodies and some trials support RFA for facet-mediated pain and report potential benefit for BVNA in selected patients with Modic type 1 or 2 changes, while technology assessments (Hayes, ECRI) and the policy evaluation note limitations in the evidence base and conclude that support is limited or minimal in some contexts.

Status is CURRENT and the subject is ablative treatments for spinal pain (radiofrequency and intraosseous BVN ablation). The document highlights key practice points from professional societies (eg, use of diagnostic medial branch blocks before facet RFA, suggested frequency limits for repeat procedures) and emphasizes that patient selection, documented imaging (Modic changes for BVNA candidates), and prior conservative therapy should be recorded when considering these procedures.

Display thresholds and dates

Pain severity threshold (NICE)VAS ≥ 5

ODI responder definitions (study thresholds)ODI minimal clinically important difference ≥ 10 or ≥ 15 points; responder defined also as ≥50% pain reduction

Policy last review date2026-03-01

Evidence-derived criteria and practice points

Evidence summary and guideline-derived practice points

Summarized findings, recommendations and suggested clinical criteria from evidence reviews and professional society guidelines:

ALL of the following

BVNA clinical evidence: Intraosseous basivertebral nerve ablation (BVNA/Intracept) has clinical studies showing clinically meaningful improvements in pain and function through 3 years in selected patients with vertebrogenic chronic low back pain (CLBP) and Modic type 1 or 2 changes, but limitations include open-label designs, industry sponsorship, small sample sizes, and lack of long-term comparators.
Systematic review findings: Systematic review (Conger 2021) found moderate-quality evidence suggesting BVN radiofrequency neurotomy is effective in reducing pain and disability in CLBP with type 1 or 2 Modic changes; 3-month ≥50% pain reduction ranged 45%-63%; ODI ≥10-point improvement 75%-93%.
HTA assessments: Hayes (2021, updated 2025) and ECRI (2020b, updated 2024) assessments find limited/ minimal support overall; one sham RCT did not convincingly show advantages over sham while another RCT showed short-term advantages versus continued standard care; further high-quality, non–industry-funded studies are needed.
SMART trial (Fischgrund et al. 2018) randomized sham-controlled trial: at 3 months treatment arm ODI decreased 20.5 points vs 15.2 in sham; responder (ODI ≥10) 75.6% vs 55.3% in sham; extension studies reported sustained improvements but had crossover and other limitations.
INTRACEPT RCT: Khalil et al. (INTRACEPT RCT) showed superiority vs standard care at interim/3 months with large ODI and VAS improvements; limitations include lack of blinding and potential bias.
Long-term pooled outcomes: Pooled and long-term analyses report sustained improvements through 3–5 years in some studies, reductions in opioid use and health care utilization, but are limited by open-label designs, industry sponsorship, and high crossover rates in RCTs.
Professional guideline summaries: Professional society recommendations (ASIPP, ASRA, NASS, NICE) broadly: support for thermal RFA for facet-mediated LBP (moderate evidence) with suggested use after diagnostic blocks and with repeat frequency typically limited to approximately twice per year; NICE recommends referral for RFA when nonsurgical treatments have failed, main pain source is medial branch–supplied structures, pain VAS ≥5, and after positive diagnostic medial branch block.

Overall confidence in the evidence is moderate to low and the brief characterizes the evidence as mixed. External HTA/assessment bodies (Hayes, ECRI) have described only limited or minimal support for BVNA, citing inconsistent randomized trial results.

Major limitations across the BVNA literature include open-label designs, substantial industry sponsorship or manufacturer involvement, small sample sizes, crossover from control arms, and reliance on subjective outcomes. These features reduce certainty and increase risk of bias.

Given these gaps and limitations, higher-quality, multicenter, blinded randomized controlled trials that are not industry-funded and that include longer-term comparators are recommended to strengthen confidence in efficacy and safety estimates.

What providers must document and billing considerations

Documentation Required

Confirm Modic changes for BVNA candidates

Evidence and trials specify BVNA candidates had Modic type 1 or 2 vertebral endplate changes between L3 and S1 documented on imaging; providers should document these findings when considering BVNA.

Imaging location: L3–S1 vertebral levels (Modic type 1 or 2)

Documentation Required

Use diagnostic medial branch block before facet RFA

Professional guidelines recommend a positive response to diagnostic medial branch block prior to performing radiofrequency denervation for facet joint pain; document diagnostic block results (for example, ≥50% pain relief).

Suggested threshold: ≥50% pain relief on diagnostic medial branch block

Billing Rule

Procedure frequency limits (guideline-based)

Guidelines suggest limits on repeat RFA procedures: generally no more than about two times per year per region, with intervals of at least 6 months when 50% or greater relief is obtained for 5–6 months; if multiple regions are treated, allow intervals of no sooner than 1–2 weeks between regions if procedures are not performed in one setting.

No more than about 2 times per year per region
Intervals ≥ 6 months if ≥50% relief sustained for 5–6 months
If multiple regions treated, allow 1–2 week spacing between regions (or treat all regions at same time if safe)

Documentation Required

Report clinical outcomes and prior conservative therapy

Trials and assessments emphasize failure of prior nonsurgical/conservative therapies before referral for ablative procedures; providers should document prior conservative treatments, clinical outcomes, and durations when requesting coverage.

Document prior nonsurgical/conservative treatments (e.g., physical therapy, injections, medications)
Document durations and response to those treatments
Report clinical outcomes (pain scores, functional measures like ODI) prior to referral

Clinical evidence, trials, and guideline context

The background summarizes clinical evidence for a range of ablative procedures. For BVNA/Intracept, randomized trials include the sham-controlled SMART trial (Fischgrund et al. 2018) which showed greater mean ODI improvement at 3 months in the treatment arm versus sham and higher responder rates, and the INTRACEPT randomized study (Khalil et al. 2019) that demonstrated superiority versus continued standard care at early time points. Multiple pooled and follow-up analyses report sustained improvements through 3 to 5 years in treated cohorts, though many were open-label with crossover.

Systematic reviews and meta-analyses (eg, Conger 2021; Mekhail et al. 2023; Nwosu 2023) generally found that BVNA is associated with clinically meaningful reductions in pain and disability in patients with Modic type 1 or 2 changes, but emphasized limited study numbers, heterogeneity, and potential manufacturer-related bias and called for further high-quality research.

Hayes (2021, updated 2025) and the ECRI assessment (2020b, updated 2024) concluded that overall support is limited or minimal: one sham RCT did not show clinically meaningful advantage over sham, while another RCT showed short-term benefits versus standard care; both assessments highlighted risk of bias, inconsistent results, and the need for multicenter, blinded RCTs.

For thermal RFA and related ablative techniques, professional society guidance (ASIPP, ASRA, NASS, NICE) supports medial branch RFA for facet-mediated LBP when selection criteria are met (eg, positive diagnostic medial branch blocks), recommends procedure frequency limits (commonly ~two times per year per region with intervals of at least 6 months), and applies severity thresholds for referral (eg, NICE: VAS ≥ 5), while noting variable evidence strength across devices and techniques.

Study	Key outcome / finding
SMART trial (Fischgrund et al. 2018)	Randomized double-blind sham RCT: at 3 months treatment ODI decreased 20.5 points vs 15.2 in sham; ODI ≥10 responder 75.6% vs 55.3%; open‑label extensions reported sustained improvements but high crossover and other limitations
INTRACEPT (Khalil et al., 2019)	Randomized open‑label RCT vs standard care: interim 3‑month adjusted ODI difference 20.9 points (25.3 vs −4.4; p<0.001); led to early crossover; lack of blinding is a limitation
Pooled / long‑term outcomes (Smuck et al. 2023; Khalil/McCormick pooled analyses 2024)	Aggregate 3‑ to 5‑year data show durable, clinically meaningful mean reductions in pain and ODI (eg, 3‑yr mean ODI reduction ~31 points; 5‑yr mean ODI reduction ~28 points), responder rates high and reductions in opioid use and health‑care utilization; studies largely open‑label, industry‑sponsored, and without long‑term comparators
Hayes and ECRI assessments (Hayes 2021/2025; ECRI 2020b/2024)	Health technology assessments conclude limited/minimal support overall: one sham RCT showed small between‑group gains, another RCT favored standard care comparator short‑term; both note risk of bias, industry sponsorship, and need for larger blinded RCTs

Definitions

BVNABasivertebral nerve ablation; intraosseous radiofrequency ablation of the basivertebral nerve (eg, Intracept system) for vertebrogenic chronic low back pain.

ODIOswestry Disability Index, a validated measure of functional disability related to low back pain.

Modic changesMRI signal changes of vertebral endplates classified as Type 1 or 2 associated with vertebrogenic pain.

Study outcomes and evidence gaps

Synthesis of the available statistics indicates a mixed evidence base: systematic reviews and pooled analyses report clinically meaningful improvements for BVNA in selected patients with Modic changes, with some studies reporting durability out to 3 years (and pooled reports up to 5 years), and responder rates in several reports in the range of substantial proportions (eg, ODI and ≥50% pain reduction outcomes).

At the same time, technology assessments (Hayes, ECRI) and the policy note that the overall quality of evidence is limited, and key evidence gaps remain, primarily the need for higher-quality, non–industry-funded randomized trials with blinding and long-term comparators.

Evidence items

SMART trial (Fischgrund et al. 2018)At 3 months ODI decreased 20.5 points (treatment) vs 15.2 points (sham); ODI ≥10 responder 75.6% vs 55.3% in sham.

INTRACEPT (Khalil et al.)At 3 months mean ODI change 25.3 points (RFA) vs -4.4 points (standard care); adjusted difference 20.9 points (p < 0.001).

Pooled/long-term BVNA outcomesResponder rates and sustained improvements reported through 3–5 years (eg, mean ODI reductions ~28–31 points at 3–5 years; NPS improvements ~4+ points); opioid use reductions up to ~74% in pooled analyses.

Hayes / ECRI conclusionsHayes (2021, updated 2025): minimal support; one RCT did not convincingly show advantages over sham while another showed short-term advantage vs standard care. ECRI (2020b, updated 2024): too few data, inconsistent RCT results, need for multicenter blinded RCTs.

OpenPayer

Ablative Treatment for Spinal Pain (for New Mexico Only)

Coverage summary

Evidence-derived criteria and practice points

What providers must document and billing considerations

Clinical evidence, trials, and guideline context

Coding

Study outcomes and evidence gaps

Revision history